Effects of trichostatin A on HIF-1α and VEGF expression in human tongue squamous cell carcinoma cells in vitro

Oncology Reports

Volumn 28, Issue 1, 2012, Pages 193-199

  Kang, Fei Wu ^a   Que, Lin ^a   Wu, Min ^a   Wang, Zuo Lin ^a   Sun, Jing ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Angiogenesis; Hypoxia inducible factor 1 ; Tongue squamous cell carcinoma; Trichostatin A

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; TRICHOSTATIN A; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CELL CYCLE ARREST; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; TONGUE CARCINOMA; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL CYCLE CHECKPOINTS; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; TONGUE NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861549063     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1784     Document Type: Article

References (55)

1. Guillemin K and Krasnow MA: The hypoxic response: huffing and HIFing. Cell 89: 9-12, 1997. (Pubitemid 27180579)
2. Ryan HE, Lo J and Johnson RS: HIF-1α is required for solid tumor formation and embryonic vascularization. EMBO J 17: 3005-3015, 1998. (Pubitemid 28254373)
3. Kim KW, Bae SK, Lee OH, et al: Insulin-like growth factor II induced by hypoxia may contribute to angiogenesis of human hepatocellular carcinoma. Cancer Res 58: 348-351, 1998.
4. Höckel M, Schlenger K, Mitze M, et al: Hypoxia and radiation response in human tumors. Semin Radiat Oncol 6: 3-9, 1996. (Pubitemid 26029370)
5. Höckel M and Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93: 266-276, 2001. (Pubitemid 32219813)
6. Ellis L, Hammers H and Pill R: Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280: 145-153, 2009.
7. Wenger RH and Gassman M: Oxygen and the hypoxia-inducible factor-1. J Biol Chem 378: 609-616, 1997.
8. Nor JE, Christensen J, Mooney DJ, et al: Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154: 375-384, 1999. (Pubitemid 29094088)
9. Gupta K, Kshirsagar S, Li W, et al: VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res 247: 495-504, 1999. (Pubitemid 29394787)
10. Baek JH, Jang JE, Kang CM, et al: Hypoxia-induced VEGF enhances tumor survivability via suppression of serum deprivation-induced apoptosis. Oncogene 19: 4621-4631, 2000.
11. Waltenberger J, Mayr U, Pentz S, et al: Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation 94: 1647-1654, 1996. (Pubitemid 26320271)
12. Myoung SK, Kwon HJ, Lee YM, et al: Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med 7: 437-443, 2001. (Pubitemid 32298546)
13. 2 homeostasis. Curr Opin Genet Dev 8: 588-594, 1998.
14. Kallio PJ, Pongratz I, Gradin K, et al: Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conformational change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci USA 94: 5667-5672, 1997. (Pubitemid 27241827)
15. Epstein AC, Gleadle JM, McNeill LA, et al: Elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54, 2001. (Pubitemid 32972036)
16. Ivan M, Konda K, Yang H, et al: HIF-1α targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science 292: 464-468, 2001. (Pubitemid 32335941)
17. 2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.
18. Salceda S and Caro J: Hypoxia-inducible factor-1α protein is rapidly degraded by the ubiquitin-proteosome system under normoxic conditions: its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 272: 22642-22647, 1997. (Pubitemid 27386079)
19. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 95: 7987-7992, 1998.
20. Maxwell PH, Wiesener MS, Chang GW, et al: The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999. (Pubitemid 29246458)
21. Ema M, Hirota K, Mimura J, et al: Molecular mechanisms of transcription activation by HLF and HIF 1alpha in response to hypoxia: their stabilization and redox signal-induced interaction with CBP/p300. EMBO J 18: 1905-1914, 1999. (Pubitemid 29158534)
22. Huang LE, Arany Z, Livingston DM and Bunn HF: Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem 271: 32253-32259, 1996. (Pubitemid 26422262)
23. Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 1996.
24. Grunstein M: Histone acetylation in chromatin structure and transcription. Nature 389: 349-352, 1997.
25. Kawaguchi Y, Kovacs JJ, McLaurin A, et al: The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 115: 727-738, 2003. (Pubitemid 38030301)
26. Hubbert C, Guardiola A, Shao R, et al: HDAC6 is a microtubule-associated deacetylase. Nature 417: 455-458, 2002. (Pubitemid 34563539)
27. Matsuyama A, Shimazu T, Sumida Y, et al: In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation. EMBO J 21: 6820-6831, 2002. (Pubitemid 36014554)
28. Kouraklis G and Theocharis S: Histone deacetylase inhibitors and anticancer therapy. Curr Med Chem Anti-Cancer Agents 2: 477-484, 2002. (Pubitemid 34649886)
29. Rosato RR and Grant S: Histone deacetylase inhibitors in cancer therapy. Cancer Biol Ther 2: 30-37, 2003.
30. Kosugi H, Towatari M, Hatano S, et al: Histone deacetylase inhibitors are the potent inducer/enhancer of differentiation in acute myeloid leukemia: a new approach to anti-leukemia therapy. Leukemia 13: 1316-1324, 1999. (Pubitemid 29429756)
31. Balanos GM, Dorrington KL and Robbins PA: Desferrioxamine elevates pulmonary vascular resistance in humans: potential for involvement of HIF-1. J Appl Physiol 92: 2501-2507, 2002. (Pubitemid 34666376)
32. Ardyanto TD, Osaki M, Tokuyasu N, et al: CoCl2-induced HIF-1α expression correlates with proliferation and apoptosis in MKN-1 cells: a possible role for the PI3K/Akt pathway. Int J Oncol 29: 549-555, 2006.
33. Abasolo I, Wang Z, Montuenga LM, et al: Adrenomedullin inhibits prostate cancer cell proliferation through a cAMP independent autocrine mechanism. Biochem Biophys Res Commun 322: 878-886, 2004. (Pubitemid 39164434)
34. Martin SJ, Reutelingsperger CP, McGahon AJ, et al: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182: 1545-1556, 1995.
35. Leong DT, Gupta A, Bai HF, et al: Absolute quantification of gene expression in biomaterial research using real-time PCR. Biomaterials 28: 203-210, 2007. (Pubitemid 44537394)
36. Lee SW, Han SI, Kim HH, et al: TAK1-dependent activation of AP-1 and c-Jun N-terminal kinase by receptor activator of NF-jB, J Biochem Mol Biol 35: 371-376, 2002. (Pubitemid 34868675)
37. Chun YS, Choi E, Kim GT, et al: Cadmium blocks hypoxia-inducible factor (HIF)-1-mediated response to hypoxia by stimulating the proteasome-dependent degradation of HIF-1α. Eur J Biochem 267: 4198-4204, 2000. (Pubitemid 30436116)
38. Krishnamachary B, Berg-Dixon S, Kelly B, et al: Regulation of colon carcinoma cell invasion by hypoxia-inducible factor-1. Cancer Res 63: 1138-1143, 2003. (Pubitemid 36278449)
39. Carmeliet P, Dor Y, Herbert JM, et al: Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-490, 1998. (Pubitemid 28373960)
40. Shweiki D, Itin A, Soffer D, et al: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: 843-845, 1992.
41. Fenrick R and Hiebert SW: Role of histone deacetylases in acute leukemia. J Cell Biochem (Suppl) 30-31: 194-202, 1998. (Pubitemid 29028741)
42. Kung AL, Wang S, Klco JM, et al: Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat Med 6: 1335-1340, 2000. (Pubitemid 32001016)
43. Semenza GL: Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35: 71-103, 2000.
44. Kwon HJ, Kim MS, Kim MJ, et al: Histone deacetylase inhibitor FK228 inhibits tumor angiogenesis. Int J Cancer 97: 290-296, 2002. (Pubitemid 34049018)
45. Vigushin DM, Ali S, Pace PE, et al: Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin Cancer Res 7: 971-976, 2001. (Pubitemid 32708736)
46. Lee YM, Kim SH, Jin Son M, et al: Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity. Biochem Biophys Res Commun 300: 241-624, 2003.
47. Liu LT, Chang HC, Chiang LC, et al: Histone deacetylase inhibitor up-regulates RECK to inhibit MMP-2 activation and cancer cell invasion. Cancer Res 63: 3069-3072, 2003.
48. Zhang QZ, Tang XD, Liu QY, et al: Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1A and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther 4: 1465-1473, 2005.
49. Yoshida M, Kijima M, Akita M, et al: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem 265: 17174-17179, 1990.
50. Xiao H, Hasegawa T and Isobe K: p300 collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem 275: 1371-1376, 2000. (Pubitemid 30051195)
51. Song Y, Wang WX, Qu X, et al: Effects of hypoxia inducible factor-1α on the growth and adhesion in tongue squamous cell carcinoma cells. Indian J Med Res 129: 154-163, 2009.
52. Blagosklonny MV, An WG, Romanova LY, et al: p53 inhibits hypoxia-inducible factor-stimulated transcription. J Biol Chem 273: 11995-11998, 1998. (Pubitemid 28240554)
53. Akakura N, Kobayashi M, Horiuchi I, et al: Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 61: 6548-6554, 2001. (Pubitemid 32783263)
54. Strait KA, Dabbas B, Hammond EH, et al: Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther 1: 1181-1190, 2002.
55. Kim YB, Ki SW, Yoshida M, et al: Mechanism of cell cycle arrest caused by histone deacetylase inhibitors in human carcinoma cells. J Antibiot 53: 1191-1200, 2000.